Drugs / PL225B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01779336 | Dec 2012 → Nov 2014 | refractory malignant neoplasm | Piramal Enterprises Limited | Suspended | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PL225B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01779336 ↗ |
| Action | Inhibit | “oral IGF-1R inhibitor PL225B” NCT01779336 ↗ |
| Route | Oral | “oral IGF-1R inhibitor PL225B” NCT01779336 ↗ |
| Target | IGF1R | “oral IGF-1R inhibitor PL225B” NCT01779336 ↗ |